CD16a, AlpHcAbs® Human Alpaca Monoclonal Antibody
cat.: HA710339
| Product Type: | Alpaca monoclonal VHH domain of alpaca IgG2b/2c fused to Human IgG1 Fc(mutation), primary antibodies |
|---|---|
| Species reactivity: | Human |
| Applications: | ELISA, FC |
| Clonality: | Monoclonal |
| Form: | Liquid |
| Storage condition: | Store at –20 ℃, (Avoid freeze / thaw cycles), Stable for 12 months at -20℃ |
| Storage buffer: | Liquid, 10mM PBS (pH 7.5), 0.05% sucrose, 0.1% trehalose, 0.01% proclin300, 50% Glycerol |
| Concentration: | 1ug/ul |
| Purification: | Immunogen affinity purified. |
| Isotype: | VHH domain of alpaca IgG2b/2c fused to Human IgG1 Fc(mutation) |
| Immunogen: | Recombinant human CD16a |
| Subcellular location: | Cell membrane, Secreted |
| Recommended Dilutions:
ELISA FC |
1:4,000-1:10,000 1:200-1:1,000 |
| Uniprot #: | SwissProt: P08637 Human |
| Alternative names: | CD 16 CD 16a CD16 CD16a CD16a antigen CD16B CD16b antigen Fc fragment of IgG Fc fragment of IgG low affinity IIIa receptor (CD16) Fc fragment of IgG low affinity IIIa receptor Fc fragment of IgG receptor IIIa Fc fragment of IgG low affinity III receptor (CD16) Fc fragment of IgG low affinity III receptor for (CD16) Fc fragment of IgG low affinity IIIa receptor (CD16) Fc fragment of IgG low affinity IIIa receptor (CD16a) Fc fragment of IgG low affinity IIIa receptor for Fc fragment of IgG low affinity IIIb receptor (CD16b) Fc fragment of IgG low affinity IIIb receptor for (CD16) Fc gamma R3 Fc gamma receptor III 2 (CD 16) Fc gamma receptor III A Fc gamma receptor IIIA Fc gamma receptor IIIb (CD 16) Fc gamma RIII alpha Fc gamma RIII Fc gamma RIII beta Fc gamma RIIIa Fc gamma RIIIb Fc of IgG Fc-gamma receptor III2 (CD 16) Fc-gamma receptor III2 (CD16) Fc-gamma receptor IIIb (CD16) Fc-gamma RIII Fc-gamma RIII-alpha Fc-gamma RIIIa FCG 3 FCG...... |
Images
|
Fig1:
Advantages of using an Alpaca Recombinant Secondary 1. Smaller size Nanobodies are 1/10 the size of a traditional antibody (~15 kDa unconjugated). This means that the nanobody can penetrate tissue faster and deeper than other antibodies. 2. Easier to use Due to their simple structure, nanobodies also have the advantage of increased stability and ease of use. 3. Easier production When compared to a more traditional antibody, nanobodies are easier to develop and produce in the lab than monoclonal or polyclonal antibodies. 4. More consistent Since nanobodies are recombinantly produced from clonal DNA, you are guaranteed the same product every time. Comparatively, polyclonal antibodies are produced in live animals and have a very low lot-to-lot consistency while monoclonal antibodies can suffer from drift. 5. Higher Affinity Nanobodies benefit from consistently high binding affinity values. |
Note: All products are “FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE”.